• In early February 2026, Relay Therapeutics announced that the FDA granted Breakthrough Therapy designation to zovegalisib (RLY-2608) plus fulvestrant for adults with PIK3CA‑mutant HR+/HER2‑ locally advanced or metastatic breast cancer after progression on CDK4/6 inhibitor treatment.
• This designation, supported by Phase 1/2 ReDiscover trial data across a broad range of PIK3CA mutations and dosing regimens, gives Relay closer FDA engagement and an expedited development path for its breast cancer program.
• We’ll now examine how this Breakthrough Therapy designation for zovegalisib may shape Relay Therapeutics’ investment narrative in oncology drug development.

We've uncovered the 14 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

What Is Relay Therapeutics' Investment Narrative?

To own Relay Therapeutics, you have to believe its precision oncology platform can turn promising early data into approved drugs despite ongoing losses and heavy cash burn. The Breakthrough Therapy designation for zovegalisib sharpens that thesis: it raises the profile of Relay’s breast cancer program and could pull some regulatory and development milestones closer, which matters for a company not expected to reach profitability soon. It also puts more investor attention on the Phase 3 ReDiscover-2 readout and any future updates from the triplet regimens, likely reinforcing these as the main near term catalysts. At the same time, the stock’s strong 1‑year run and continued unprofitability keep trial risk, financing needs and recent insider selling firmly in focus.

However, one risk in particular is easy to underestimate until you look closer. In light of our recent valuation report, it seems possible that Relay Therapeutics is trading beyond its estimated value.

Exploring Other Perspectives

Explore another fair value estimate on Relay Therapeutics - why the stock might be worth just $14.55!

Build Your Own Relay Therapeutics Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Relay Therapeutics research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Relay Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Relay Therapeutics' overall financial health at a glance.

Looking For Alternative Opportunities?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• The latest GPUs need a type of rare earth metal called Terbium and there are only 29 companies in the world exploring or producing it. Find the list for free.
• This technology could replace computers: discover 22 stocks that are working to make quantum computing a reality.
• Find 52 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.